The essential thrombocythemia in 2020: what we know and where we still have to dig deep

V Accurso, M Santoro, S Mancuso… - Clinical Medicine …, 2020 - journals.sagepub.com
The Essential Thrombocythemia is a Chronic Philadelphia-negative Myeloproliferative
Neoplasm characterized by a survival curve that is only slightly worse than that of age-and …

Aetiology of myeloproliferative neoplasms

MF McMullin, LA Anderson - Cancers, 2020 - mdpi.com
Myeloproliferative neoplasms (MPNs) have estimated annual incidence rates for
polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis of 0.84 …

A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia

B Rocca, A Tosetto, S Betti, D Soldati… - Blood, The Journal …, 2020 - ashpublications.org
Essential thrombocythemia (ET) is characterized by abnormal megakaryopoiesis and
enhanced thrombotic risk. Once-daily low-dose aspirin is the recommended antithrombotic …

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial

ST Oh, M Talpaz, AT Gerds, V Gupta… - Blood …, 2020 - ashpublications.org
Momelotinib (MMB) is a JAK1/2 and ACVR1 inhibitor with demonstrated clinical activity in all
3 hallmarks of myelofibrosis (MF): anemia, constitutional symptoms, and splenomegaly. In …

Efficacy of ruxolitinib in patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia

KHT Dao, J Gotlib, MMN Deininger, ST Oh… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Colony-stimulating factor-3 receptor (CSF3R)-T618I is a recurrent activating
mutation in chronic neutrophilic leukemia (CNL) and to a lesser extent in atypical chronic …

MERGE: a multinational, multicenter observational registry for myeloproliferative neoplasms in Asia, including Middle East, Turkey, and Algeria

MA Yassin, A Taher, V Mathews, HA Hou… - Cancer …, 2020 - Wiley Online Library
Abstract Philadelphia chromosome‐negative (Ph−) myeloproliferative neoplasms (MPNs)
are a heterogeneous group of clonal disorders of the bone marrow, and are associated with …

[HTML][HTML] Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis

K Hartmann, J Gotlib, C Akin, O Hermine… - Journal of Allergy and …, 2020 - Elsevier
Background Advanced systemic mastocytosis (advSM) is characterized by presence of the
KIT D816V mutation and pathologic accumulation of neoplastic mast cells (MCs) in various …

Associations between global mental health and response to an app-based meditation intervention in myeloproliferative neoplasm patients

ME Puzia, J Huberty, R Eckert… - Integrative cancer …, 2020 - journals.sagepub.com
Background: Depression, anxiety, and sleep disturbance are common problems that greatly
affect quality of life for many myeloproliferative neoplasm (MPN) patients. App-based …

The next generation of JAK inhibitors: an update on fedratinib, momelotonib, and pacritinib

AA Patel, O Odenike - Current Hematologic Malignancy Reports, 2020 - Springer
Abstract Purpose of Review Ruxolitinib is the first FDA-approved JAK inhibitor for the
treatment of myeloproliferative neoplasms and is an effective means of controlling symptom …

Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study

A Rambaldi, A Iurlo, AM Vannucchi, R Noble… - Leukemia, 2020 - nature.com
Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (cMPN) characterized by
stem cell-derived clonal myeloproliferation resulting in panmyelosis with persistently raised …